


# Rilpivirine PK Fact Sheet

 Produced by [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org) (October 2011)

Page 1 of 2

## Details

<i>Generic Name</i>	Rilpivirine
<i>Trade Name</i>	Edurant®
<i>Class</i>	Non-Nucleoside Reverse Transcriptase Inhibitor
<i>Molecular Weight</i>	402.88
<i>Structure</i>	



## Summary of Key Pharmacokinetic Parameters

<i>Linearity/non-linearity</i>	Over the dose range 25-150 mg once daily, plasma concentrations obtained following administration of a tablet formulation to healthy volunteers increased in a dose-proportional manner [1].
<i>Steady state</i>	Steady state is anticipated to be achieved in ~10-15 days [2].
<i>Plasma half life</i>	~50 h
<i>C<sub>max</sub></i>	204 ± 76 ng/ml (n=12, healthy volunteers) [1] (Population PK estimate not available)
<i>C<sub>min</sub></i>	67 ± 30 ng/ml (n=12, healthy volunteers) [1] 74 (1-300) ng/ml, predicted median (range) from population PK modelling (n=679, HIV+)
<i>AUC</i>	2589 ± 869 ng.h/ml (n=12, healthy volunteers) [1] 2204 (482-8601) ng.h/ml, predicted median (range) from population PK modelling (n=679, HIV+)
<i>Bioavailability</i>	Absolute bioavailability not determined due to lack of an IV formulation [2]
<i>Absorption</i>	The exposure to rilpivirine was approximately 40% lower when rilpivirine was taken in a fasted condition as compared to a normal caloric meal (533 kcal) or high fat high-caloric meal (928 kcal). When rilpivirine was taken with only a protein rich nutritional drink, exposures were 50% lower than when taken with a meal.
<i>Protein Binding</i>	99.7%
<i>Volume of Distribution</i>	~152 L [2]
<i>CSF:Plasma ratio</i>	Not evaluated in humans
<i>Semen:Plasma ratio</i>	Not evaluated in humans
<i>Renal Clearance</i>	<1% as unchanged drug

# Rilpivirine PK Fact Sheet

Produced by [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org) (October 2011)

Page 2 of 2

<i>Renal Impairment</i>	No dose adjustment is required in patients with mild or moderate renal impairment. However, in patients with severe renal impairment or end-stage renal disease, rilpivirine should be used with caution and with increased monitoring for adverse effects, as rilpivirine concentrations may be increased due to alteration of drug absorption, distribution, and metabolism secondary to renal dysfunction. As rilpivirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis.
<i>Hepatic Impairment</i>	In a study comparing 8 subjects with mild hepatic impairment (Child-Pugh score A) to 8 matched controls, and 8 subjects with moderate hepatic impairment (Child-Pugh score B) to 8 matched controls, the multiple dose exposure of rilpivirine was 47% higher in subjects with mild hepatic impairment and 5% higher in subjects with moderate hepatic impairment. No dose adjustment is required in patients with mild or moderate hepatic impairment. Rilpivirine has not been studied in subjects with severe hepatic impairment (Child-Pugh score C).

## Metabolism and Distribution

<i>Metabolised by</i>	Primarily CYP 3A. Potential contribution from CYP2A19 [2].
<i>Inducer of</i>	At the recommended dose of 25 mg once daily, rilpivirine is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.
<i>Inhibitor of</i>	At the recommended dose of 25 mg once daily, rilpivirine is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Based on in vitro results with 25 mg once daily, rilpivirine may act as a P-gp inhibitor [2].
<i>Transported by</i>	Not significantly transported by P-gp [2].

## References

Unless otherwise stated (see below), information is from:

Edurant® US Prescribing Information, Tibotec Inc, May 2011.

1. Hoetelmans R, Van Heeswijk R, Kestens D, *et al.* Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation. 3<sup>rd</sup> IAS Conference on HIV Pathogenesis and Treatment, Brazil, July 2005, abstract TuPe3.1B10.
2. FDA, Rilpivirine Clinical Pharmacology and Biopharmaceutics Review (NDA 202-022)  
[http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2011/202022Orig1s000TOC.cfm](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202022Orig1s000TOC.cfm)